Dohj LLC Has $759,000 Holdings in Agilent Technologies, Inc. (NYSE:A)

Dohj LLC cut its holdings in Agilent Technologies, Inc. (NYSE:A) by 30.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,461 shares of the medical research company’s stock after selling 2,379 shares during the period. Dohj LLC’s holdings in Agilent Technologies were worth $759,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in A. Massachusetts Financial Services Co. MA boosted its position in Agilent Technologies by 0.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 11,076,270 shares of the medical research company’s stock worth $1,238,549,000 after purchasing an additional 39,030 shares during the period. Wellington Management Group LLP raised its stake in Agilent Technologies by 17.4% in the third quarter. Wellington Management Group LLP now owns 10,255,526 shares of the medical research company’s stock valued at $1,146,773,000 after purchasing an additional 1,519,134 shares in the last quarter. Northern Trust Corp raised its stake in Agilent Technologies by 6.6% in the third quarter. Northern Trust Corp now owns 4,097,313 shares of the medical research company’s stock valued at $458,162,000 after purchasing an additional 254,998 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Agilent Technologies by 4.9% in the third quarter. Bank of New York Mellon Corp now owns 2,677,277 shares of the medical research company’s stock valued at $299,373,000 after purchasing an additional 124,671 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in Agilent Technologies by 233.7% in the fourth quarter. Nordea Investment Management AB now owns 2,666,416 shares of the medical research company’s stock valued at $370,552,000 after purchasing an additional 1,867,377 shares in the last quarter.

Agilent Technologies Stock Performance

Agilent Technologies stock traded up $1.37 during midday trading on Friday, reaching $137.74. The stock had a trading volume of 754,945 shares, compared to its average volume of 1,245,651. Agilent Technologies, Inc. has a 12 month low of $96.80 and a 12 month high of $151.58. The firm’s 50-day moving average price is $141.59 and its 200 day moving average price is $130.68. The firm has a market capitalization of $40.36 billion, a PE ratio of 32.80, a P/E/G ratio of 4.17 and a beta of 1.11. The company has a quick ratio of 2.04, a current ratio of 2.68 and a debt-to-equity ratio of 0.41.

Agilent Technologies (NYSE:A) last posted its earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. The business had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The company’s quarterly revenue was down 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.37 EPS. As a group, research analysts predict that Agilent Technologies, Inc. will post 5.5 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd were issued a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend was Monday, April 1st. Agilent Technologies’s payout ratio is 22.38%.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 52,297 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $150.00, for a total value of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares of the company’s stock, valued at $38,086,350. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the sale, the director now owns 54,976 shares in the company, valued at $7,935,235.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael R. Mcmullen sold 52,297 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $150.00, for a total value of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares of the company’s stock, valued at approximately $38,086,350. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 61,610 shares of company stock valued at $9,220,333.

Analyst Ratings Changes

Several research analysts have commented on A shares. Stifel Nicolaus raised Agilent Technologies from a “hold” rating to a “buy” rating and boosted their target price for the stock from $145.00 to $163.00 in a research note on Friday, April 5th. Barclays boosted their target price on Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Evercore ISI upped their price objective on Agilent Technologies from $132.00 to $145.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Oppenheimer upped their price objective on Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Finally, UBS Group upped their price objective on Agilent Technologies from $130.00 to $155.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $141.29.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.